Skip to main content
Medical information Clinical review pending

Genetic Testing

SCA6 Spinocerebellar Ataxia CACNA1A Gene Mutation Test

The SCA6 Spinocerebellar Ataxia CACNA1A Gene Mutation Test helps identify genetic mutations linked to Spinocerebellar Ataxia Type 6 (SCA6), a condition affecting coordination and balance. This test is important for diagnosing genetic ataxia disorders.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample. Confirm specific requirements with the laboratory before booking.
Results
Results are typically available within a few days after sample receipt. Confirm exact turnaround time with the laboratory before booking.
Preparation
No special preparation is typically required for this blood test. Confirm with the laboratory before booking.
Test priceKSh 8,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the SCA6 Spinocerebellar Ataxia CACNA1A Gene Mutation Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Unexplained balance problems or coordination difficulties
  • ✓Progressive difficulty with movement or speech
  • ✓Family history of ataxia or related neurological disorders
  • ✓Symptoms suggestive of Spinocerebellar Ataxia Type 6
02

In plain language

What this test helps you understand

This test helps confirm or rule out a diagnosis of Spinocerebellar Ataxia Type 6 (SCA6) by identifying mutations in the CACNA1A gene. It aids in understanding the genetic cause of ataxia symptoms and can inform prognosis and family planning.
The SCA6 Spinocerebellar Ataxia CACNA1A Gene Mutation Test is a diagnostic tool used to identify specific genetic mutations associated with Spinocerebellar Ataxia Type 6 (SCA6). SCA6 is a neurological condition characterized by progressive problems with coordination, balance, and movement.

This test focuses on the CACNA1A gene. Mutations within this gene are known to cause SCA6 and other neurological disorders. Understanding the genetic basis of ataxia can be crucial for diagnosis, management, and family planning.

Early and accurate diagnosis through genetic testing can help patients and their families understand the condition, access appropriate care, and make informed decisions about the future.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for this blood test. Confirm with the laboratory before booking.
SampleBlood sample. Confirm specific requirements with the laboratory before booking.
MethodologyGenetic analysis of the CACNA1A gene, typically using methods like DNA sequencing. Confirm specific methodology with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically looks for mutations in the CACNA1A gene associated with SCA6. It may not detect all possible genetic causes of ataxia. A negative result does not completely rule out SCA6 or other forms of ataxia. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

SCA6 is a genetic neurological disorder that causes progressive problems with coordination, balance, and movement.
The CACNA1A gene provides instructions for making a protein important for the function of nerve cells, particularly in the brain.
Individuals experiencing symptoms like balance issues, coordination problems, or speech difficulties, especially with a family history of similar conditions, may be candidates for testing.
Your doctor will interpret the results with you, discuss what they mean for your health, and recommend appropriate next steps or management strategies.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
Yes, home sample collection services are available for added convenience. Please inquire when booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp